Plasma metanephrins are associated with myocardial hypertrophy and cardiac diastolic function in patients with essential hypertension

Zhou, Ying; Yuan, Jiansong; Wang, Yong; Qiao, Shubin

doi:10.25011/cim.v43i1.33581

Cited by 1 publication

(1 citation statement)

References 32 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urine CA were not found to be associated with high levels of blood pressure [ 27 ]. Regarding catecholamine metabolites, plasma metanephrines demonstrated a relationship with impaired glucose metabolism/risk of prediabetes [ 28 ], left ventricular hypertrophy, and diastolic dysfunction [ 29 ]. Coulson et al [ 30 ] observed a correlation between 24-h urinary normetanephrine and measures of SBP variability and hypothesized that sympathetic activity may influence SBP variability.…”

Section: Discussionmentioning

confidence: 99%

Association of Urine Metanephrine Levels with CardiometaBolic Risk: An Observational Retrospective Study

Parasiliti-Caprino

Obert

Lopez

et al. 2021

JCM

View full text Add to dashboard Cite

No research has explored the role of catecholamine metabolites in the stratification of cardiovascular risk. We aimed to evaluate the relationship between urine metanephrines and cardiometabolic risk/complications. In this retrospective cross-sectional study, we collected the data of 1374 patients submitted to the evaluation of urine metanephrines at the City of Health and Science University Hospital of Turin between 2007 and 2015, mainly for investigating the suspicion of secondary hypertension or the secretion of an adrenal lesion. The univariate analysis showed associations between metanephrines and cardiometabolic variables/parameters, particularly considering noradrenaline metabolite. At univariate regression, normetanephrine was associated with hypertensive cardiomyopathy (OR = 1.18, 95% CI 1.11–1.25; p < 0.001) and metabolic syndrome (OR = 1.11, 95% CI 1.03–1.20; p = 0.004), while metanephrine was associated with hypertensive cardiomyopathy (OR = 1.23, 95% CI 1.06–1.43; p = 0.006) and microalbuminuria (OR = 1.30, 95% CI 1.03–1.60; p = 0.018). At multivariate regression, considering all major cardiovascular risk factors as possible confounders, normetanephrine retained a significant association with hypertensive cardiomyopathy (OR = 1.14, 95% CI 1.07–1.22; p < 0.001) and metabolic syndrome (OR = 1.10, 95% CI 1.02–1.19; p = 0.017). Moreover, metanephrine retained a significant association with the presence of hypertensive cardiomyopathy (OR = 1.18, 95% CI 1.01–1.41; p = 0.049) and microalbuminuria (OR = 1.34, 95% CI 1.03–1.69; p = 0.019). The study showed a strong relationship between metanephrines and cardiovascular complications/metabolic alterations. Individuals with high levels of these indirect markers of sympathetic activity should be carefully monitored, and they may benefit from an aggressive treatment to reduce the cardiometabolic risk.

show abstract

Section: Discussionmentioning

confidence: 99%